Biogen Inc. (FRA:IDP)
Germany · Delayed Price · Currency is EUR | Market Cap | 18.46B |
| Revenue (ttm) | 8.51B |
| Net Income (ttm) | 1.30B |
| Shares Out | n/a |
| EPS (ttm) | 8.90 |
| PE Ratio | 14.17 |
| Forward PE | 9.49 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 370 |
| Average Volume | 365 |
| Open | 125.85 |
| Previous Close | 126.15 |
| Day's Range | 125.85 - 127.00 |
| 52-Week Range | 99.82 - 174.20 |
| Beta | n/a |
| RSI | 54.17 |
| Earnings Date | Oct 30, 2025 |
About Biogen
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial numbers in USD Financial StatementsNews
J.L. Bainbridge Exits Most of Biogen Stake as Biotech Stock Eyes Turnaround
Key PointsFlorida-based J. L. Bainbridge sold 119,376 shares of Biogen for an estimated $16.1 million in the third quarter.
Biogen (BIIB) Gains Momentum with Patient Opportunity Equity Strategy
Biogen (BIIB) Gains Momentum with Patient Opportunity Equity Strategy
Patient Opportunity Equity strategy buys UNH, CROX, MAT, IAC, and BIIB
Why InnoCare's Licensing Deal Triggered A Stock Rout
The Chinese biotech agreed to sell some of the rights to its flagship drug for a sum that could exceed $2 billion but investors were unhappy with the fine print Key Takeaways: The counterparty, Zenas ...
Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact
Biogen (BIIB) to Report Q3 Earnings Amid IPR&D Expense Impact
Biogen sees negative impact on Q3 EPS from IPR&D expense
LEQEMBI IQLIK(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME’s “Best Inventions of 2025”
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CE...
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's "Best Inventions of 2025"
TOKYO and CAMBRIDGE, Mass. , Oct. 13, 2025 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (NASDAQ: BIIB , Headquarters: Cambridge, Massachusetts , C...
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CE...
BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BIIB Stock News
BIIB: Morgan Stanley Raises Price Target for Biogen to $149 | BIIB Stock News
Biogen And Stoke Therapeutics Present Promising Long-Term Data For Zorevunersen In Dravet Syndrome
(RTTNews) - Biogen Inc. (BIIB) and Stoke Therapeutics Inc. (STOK) unveiled new long-term follow-up data from ongoing open-label extension (OLE) studies of zorevunersen, reinforcing its potential as a ...
BIIB: New Findings Highlight the Potential of Zorevunersen for Dravet Syndrome
BIIB: New Findings Highlight the Potential of Zorevunersen for Dravet Syndrome
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Syndrome
Biogen's (BIIB) Zorevunersen Shows Promise in Treating Dravet Syndrome
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal c...
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...
Biogen's Comeback: Why The Bulls Are Finally Winning Again
Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation
Biogen (BIIB) Sees Decline After Launching New Alzheimer's Drug Formulation
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug
Biogen (BIIB) and Eisai Launch New Form of Alzheimer's Drug
Eisai And Biogen : LEQEMBI IQLIK Injection Now Available In U.S. For Early Alzheimer's Treatment
(RTTNews) - Eisai Co., Ltd. (ESALY.PK, ESALF.PK, 4523.T) and Biogen Inc. (BIIB) announced the U.S. availability of LEQEMBI IQLIK (lecanemab-irmb) as a subcutaneous injection for maintenance dosing in ...
Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S.
Biogen (BIIB) Launches New Alzheimer's Treatment in the U.S.
Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S.
Biogen (BIIB) Launches New Alzheimer's Treatment Option in U.S.
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
New LEQEMBI Companion ™ program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...
Eisai and Biogen Announce U.S. Availability of LEQEMBI IQLIK (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer’s Disease
New LEQEMBI Companion program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an inj...
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...
Monday Sector Laggards: Healthcare, Consumer Products
The worst performing sector as of midday Monday is the Healthcare sector, showing a 0.6% loss. Within that group, Biogen Inc (Symbol: BIIB) and Baxter International Inc (Symbol: BAX) are two of the da...